Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERACYTE, INC.VCYT · Entity 2018 | Chief Scientific & Med Officer | December 06, 2022 | December 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERACYTE, INC.
Report date December 06, 2022 · Filed December 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,970 |
Reported balance
After 2022-12-06 transaction · row 1
1 source rowRow 1 · 2022-12-06 · Sale · Disposed 1,023 · Balance 65,970 F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $20.21 | $0.00 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · derivative · entry 11 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-27 F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 813 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · nonDerivative · entry 10 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,587 F5 · shares: The reporting person is reporting the withholding of 813 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,350 Restricted Stock Units granted on March 2, 2018. The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,300 | $21.28 | $27,668.29 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · nonDerivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,400 F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $21.14 to $21.39. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 36,075 | $20.42 | $736,536.06 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · nonDerivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,700 F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $20.11 to $21.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 12,396 | $9.05 | $112,183.80 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · nonDerivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 4,166 | $5.43 | $22,621.38 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 8,749 | $6.45 | $56,431.05 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 11,667 | $8.86 | $103,369.62 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 397 | $10.45 | $4,148.65 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,400 F2 · shares: Restricted stock units awarded on February 28, 2019 vest 25% on February 28, 2021 and 75% on February 28, 2022 subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:05 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-19-000024 · wf-form4_155174432116817.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,400 F1 · shares: Restricted stock units awarded on February 28, 2019 vest 25% on March 2, 2020 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.